Giora Davidai
About Giora Davidai
Giora Davidai serves as the Chief Medical Officer at AIT Bioscience and AIT Therapeutics Inc. since 2017, bringing over 27 years of experience in the pharmaceutical industry, particularly in drug development and medical affairs.
Work at AIT Bioscience
Giora Davidai serves as the Chief Medical Officer at AIT Bioscience, a role he has held since 2017. In this position, he oversees medical affairs and contributes to the strategic direction of the company. His responsibilities include guiding research initiatives and ensuring compliance with regulatory standards. Davidai's extensive experience in the pharmaceutical industry supports his leadership role, allowing him to influence drug development processes effectively.
Education and Expertise
Giora Davidai has a robust educational background in medicine. He earned his Doctor of Medicine (MD) from the Sackler School of Medicine at Tel Aviv University from 1974 to 1980. He completed his Pediatrics Residency Program at Haifa Medical Center in Israel, achieving Board Certification from 1980 to 1984. He further specialized in Nephrology through a Fellowship at Rambam Medical Center from 1984 to 1986. Additionally, he completed a Pediatrics Residency Program with a focus on Pediatric Nephrology at Duke University from 1986 to 1990.
Background in the Pharmaceutical Industry
With 27 years of experience in the pharmaceutical industry, Giora Davidai has held senior positions that encompass both research and development and medical affairs. His career includes significant roles at GlaxoWellcome and Boehringer Ingelheim prior to his tenure at AIT Bioscience. Davidai's expertise spans various therapeutic areas, including cardiovascular, central nervous system, metabolic, and respiratory drug development.
Consulting Role
In addition to his position as Chief Medical Officer, Giora Davidai serves as a consultant. This role allows him to leverage his extensive knowledge and experience to provide strategic insights and guidance to various projects within the pharmaceutical sector. His consulting work complements his responsibilities at AIT Bioscience and enhances his contributions to the field.